Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

R&I Affirms Takeda Pharmaceutical Co Ltd's Rating at "AA+"; Rating Outlook Stable


Wednesday, 28 Nov 2012 01:00am EST 

Rating and Investment Information, Inc. (R&I) announced that it has affirmed the rating on Takeda Pharmaceutical Co Ltd's at "AA+". The rating outlook is stable. 

Latest Key Developments in Pharmaceuticals

Company Quote

4663.0
8.0 +0.17%
11 Jul 2014